Work

I farmaci anti-obesità in età evolutiva

Year: 2026
Type: article
Abstract: The use of GLP-1 agonists has been shown to reduce weight and improve glycemic control in children by decreasing appetite and slowing gastric emptying. GLP-1 agonists act on the brain by stimulating specific receptors in areas of the central nervous system, such as the hypothalamus, thereby inducing a greater sense of satiety. They also influence gastrointestinal function by slowing gastric emptying, which helps to limit post-meal increases in lipid and carbohydrate levels. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising therapeutic option for pediatric patients, given their beneficial effects on weight reduction and glycemic regulation. Further studies are required to evaluate their long-term safety regarding growth, puberty, and bone development. Their use must be personalized and integrated with programs focusing on behavioral therapy, nutrition, and physical activity. Overall, the efficacy of GLP-1 agonists in the glycemic control of children and adolescents with type 2 diabetes mellitus is well-documented. Consequently, these medications represent a valuable adjunctive therapy for young people with type 2 diabetes mellitus who do not achieve optimal glycemic control with metformin or insulin alone.
Language: Italian
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7223716591
FWCI:
Cites: 32
Cited by:
Related to: 10